# Kailera Therapeutics, Inc.: overview

KLRA · Nasdaq · CIK 2096997 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/klra.md) · [Financials](/companies/klra/financials.md) · [Filings](/companies/klra/filings.md) · [Insiders](/companies/klra/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $ | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(17983.00)](/filings/0001193125-26-239417.md) | [(28947.00)](/filings/0001193125-26-346958.md) | [(3650.00)](/filings/0001193125-26-239417.md) | [(1.09)](/filings/0001193125-26-346958.md) |
| Free cash flow | $ | not reported | not reported | not reported | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure.

## Last five fiscal years

Not reported.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/klra/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Bain Capital Investors LLC](/funds/1040508.md) | 2026-06-30 | $578.4m | 26,255,581 |  | New +26,255,581 |
| [Bain Capital Life Sciences Investors, LLC](/funds/1703031.md) | 2026-06-30 | $497.5m | 22,583,268 |  | New +22,583,268 |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $237.4m | 10,776,820 |  | New +10,776,820 |
| [CANADA PENSION PLAN INVESTMENT BOARD](/funds/1283718.md) | 2026-06-30 | $160.9m | 7,304,688 |  | New +7,304,688 |
| [Atlas Venture Life Science Advisors, LLC](/funds/1917529.md) | 2026-06-30 | $113.9m | 5,171,282 |  | New +5,171,282 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $87.5m | 3,970,865 |  | New +3,970,865 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $86.5m | 3,928,604 |  | New +3,928,604 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $71.4m | 3,240,787 |  | New +3,240,787 |
| [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $70.7m | 3,208,286 |  | New +3,208,286 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $64.3m | 2,919,110 |  | New +2,919,110 |

## Recent filings

[All 62 filings](/companies/klra/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-12 | 16:29 ET | [10-Q](/filings/0001193125-26-346958.md) | Quarterly report, period 2026-06-30 | 0001193125-26-346958 |
| 2026-08-12 | 16:20 ET | [8-K](/filings/0001193125-26-346919.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-346919 |
| 2026-05-26 | 16:29 ET | [10-Q](/filings/0001193125-26-239417.md) | Quarterly report, period 2026-03-31 | 0001193125-26-239417 |
| 2026-05-26 | 16:18 ET | [8-K](/filings/0001193125-26-239362.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-239362 |
| 2026-04-23 | 20:01 ET | [SCHEDULE 13D](/filings/0001193125-26-174330.md) | Ownership report, active investor | 0001193125-26-174330 |
| 2026-04-23 | 19:34 ET | [SCHEDULE 13D](/filings/0001193125-26-174293.md) | Ownership report, active investor | 0001193125-26-174293 |
| 2026-04-20 | 16:19 ET | [8-K](/filings/0001193125-26-164040.md) | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-164040 |
| 2026-04-13 | 06:12 ET | [S-1/A](/filings/0001193125-26-151904.md) | Registration statement, amended | 0001193125-26-151904 |
| 2026-03-27 | 16:02 ET | [S-1](/filings/0001193125-26-128952.md) | Registration statement | 0001193125-26-128952 |

## Latest annual report

No annual report is in coverage.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 2096997
- Tickers: KLRA
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.